Avalon GloboCare Corp

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties. The Medical Related Consulting segment relates to labor and related benefits, travel expenses, and related to consulting services. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned Laboratory Services MSO, LLC (LSM) has signed an exclusive master service agreement (MSA) with GeneX Laboratory Professional Corp to be the exclusive testing provider for toxicology testing, genetic testing, and others. The developer of innovative cell-based technology, cellular therapy and precision diagnostics said GeneX has licenses with major providers such as Aetna California, United Health Care, Cigna (NYSE:CI), and Medicaid in 21 states, offering a range of high-quality testing, including Liquid Chromatography-Mass Spectrometry (LC-MS) drug testing, genetic testing, urinary testing and COVID-19 PCR testing.

Avalon GloboCare investee LSM inks lab testing deal with GeneX

MSA Signed with GeneX Laboratory, an In-Network Laboratory Licensed in Multiple States Including Medicare and Medicaid Laboratory Services MSO will be the Exclusive Testing Provider for Toxicology Testing, Genetic Testing and Others FREEHOLD, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has signed an exclusive Master Service Agreement (“MSA”) with GeneX Laboratory Professional Corp. (“GeneX”).

Avalon GloboCare's Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States

Avalon GloboCare Corp (NASDAQ:ALBT) has updated investors on its progress in implementing its new commercial strategy focused on laboratory acquisitions and diagnostics.  In a letter to shareholders, the company's CEO David Jin noted that the company intends to play a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results.

Avalon GloboCare says 2023 will be ‘pivotal year' as it executes new commercial strategy

Company Continues to Implement Major Change in Strategy Focused on Acquiring and Operating Accretive Revenue Generating Laboratories and Related Commercialized Products

Avalon GloboCare Provides Update on New Commercial Strategy

Avalon GloboCare Corp (NASDAQ:ALBT) has announced 2022 financial results for Laboratory Services MSO LLC, a clinical diagnostics and reference laboratory that Avalon acquired a 40% interest earlier this year. LSM saw revenue of $14.7 million and gross profit of $8.1 million, the company said.

Avalon GloboCare highlights the 2022 results of its latest investment, Laboratory Services MSO

40% Profit Sharing Arrangement with Laboratory Services MSO is Expected to Result in Significant Future Cash Flow to the Company 40% Profit Sharing Arrangement with Laboratory Services MSO is Expected to Result in Significant Future Cash Flow to the Company

Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022

Avalon GloboCare Corp (NASDAQ:ALBT) said it will launch its KetoAir breathalyzer device at the KetoCon Austin 2023 conference. KetoAir is a companion diagnostic and monitoring device that uses an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management.

Avalon GloboCare to launch its KetoAir breathalyzer device in North America at upcoming conference

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has signed an agreement with Qi Diagnostics Limited for exclusive distribution rights to market Qi's KetoAir breathalyzer device and related accessories, including current and future models, in North America, South America, the UK, and the European Union.  The developer of innovative cell-based technology, cellular therapy and precision diagnostics said the commercialization-ready KetoAir functions as companion diagnostic and monitoring device for ketogenic dietary management and will initially target the diabetes reversal and weight management markets.

Avalon GloboCare inks deal with Qi Diagnostics for distribution of KetoAir breathalyzer

FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has been invited to participate in the 35th Annual Roth Conference being held on March 13 and 14, 2023.

Avalon GloboCare to Participate in the 35th Annual Roth Conference

Avalon GloboCare Corp (NASDAQ:ALBT) has now completed its investment to take a 40% stake in drug testing firm Laboratory Services MSO (LSM). The California based investee, LSM, has a portfolio of testing services including diagnostic tests, drug testing, toxicology, pharmacogenetics, general bloodwork, and other specialist tests.

Avalon GloboCare excited as it closes earnings accretive investment in testing firm

Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement

Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company

Avalon GloboCare Corp (NASDAQ:ALBT) has announced that the US Patent and Trademark Office (USPTO) has issued it with US Patent No. 11,555,060, titled 'QTY Fc Fusion Water Soluble Receptor Proteins', which was jointly filed with Dr Shuguang Zhang of the Massachusetts Institute of Technology (MIT).

Avalon GloboCare says it has been issued with a US patent for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules

Patent Jointly Filed with the Massachusetts Institute of Technology (MIT) Patent Jointly Filed with the Massachusetts Institute of Technology (MIT)

Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has appointed entrepreneur and corporate finance executive Lourdes Felix to its board of directors.  The Freehold, New Jersey-based biotechnology company noted that Felix has 30 years of combined experience in capital markets, public accounting and in the private sector.

Avalon GloboCare appoints Lourdes Felix, CEO of a premier addiction treatment company, to its board

Ms. Felix's Appointment Will Support New Roll-Up Strategy Targeting Toxicology Labs, Including Within the Addiction Sector Ms. Felix's Appointment Will Support New Roll-Up Strategy Targeting Toxicology Labs, Including Within the Addiction Sector

Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors

Avalon GloboCare Corp (NASDAQ:ALBT) revealed that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The Freehold, New Jersey-based biotechnology company is enabling the development and commercialization of companion diagnostics and novel therapeutic targets for leukemia patients.

Avalon GloboCare reveals deployment of breakthrough fusion gene map technology

Enabling the Development and Commercialization of Companion Diagnostics and Novel Therapeutic Targets for Leukemia Patients Enabling the Development and Commercialization of Companion Diagnostics and Novel Therapeutic Targets for Leukemia Patients

Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has raised $4 million through a private placement of shares of its Series A preferred stock with the company's chairman, Daniel Lu. The gross proceeds are in addition to the previously announced private placement of $5 million of Series A preferred stock, all of which will be used to pay a portion of the purchase price for the announced acquisition of Laboratory Services MSO, LLC, Avalon said.

Avalon GloboCare raises $4M in Series A preferred stock to fund Laboratory Services MSO acquisition

Newly issued preferred stock convertible at a minimum of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up

Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company's Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laboratory Services

Avalon GloboCare Corp (NASDAQ:ALBT) has encouraged its shareholders to vote on a number of key proposals at its upcoming annual meeting to be held on December 29, 2022, at 11am Eastern Time. Shareholders can vote on a new proposed board composition to reflect the company's continued US focus and acquisition of Laboratory Services MSO LLC, Avalon said in a statement.

Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, reminds investors to vote in the upcoming annual meeting, which includes a new proposed Board composition to reflect its continued U.S. focus and planned acquisition of Laboratory Services MSO, LLC. On November 14, as part of its 10Q filing with the Securities and Exchange Commission, the Company disclosed its decision to cease all operations in the People's Republic of China with the exception of a small administrative office and a non-operating, patent holding entity.

Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC

Company to Begin Trading under New Symbol “ALBT” on November 10, 2022

Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”

Avalon GloboCare Corp (NASDAQ:AVCO) is set to buy a 60% stake in Laboratory Services MSO as it expands its focus on lab testing and services in what it called a 'transformative' deal worth $31 million. California-headquartered Laboratory Services has completed over 600,000 tests since inception.

News for Avalon GloboCare Corp Stock (ALBT)